Vertex Pharmaceuticals review

The short version

Vertex is a Boston biotech that did something rare: it found medicines that fix the cause of a deadly genetic disease, cystic fibrosis, and now treats most patients in the world with almost no competition. That business brought in $3.44 billion in Q3 2026, up 12%, and the full-year forecast was raised to $13.15–13.25 billion (Vertex Q3 2026 results). Vertex uses that money to make big bets: the first CRISPR medicine, a new kind of painkiller, kidney drugs and lab-grown insulin cells.

What Vertex makes

In cystic fibrosis, a faulty protein (CFTR) clogs the lungs with mucus. Vertex’s pills help that protein work again. Trikafta sold $2.44 billion in the quarter, and its once-a-day successor Alyftrek $706 million, almost three times a year earlier. Patients are moving from one to the other, which also extends Vertex’s patent protection.

The new products are still small. Casgevy, a one-time gene-editing treatment for sickle cell disease made with CRISPR Therapeutics, sold $99 million. Journavx, a pain pill, sold $58 million from 750,000 prescriptions. Palsonify joined in September 2026 with the $10 billion purchase of Crinetics.

Is it really new?

More than most. Vertex has three products that were the first of their kind: the first medicines to correct CFTR (Kalydeco in 2012, then the combinations), the first CRISPR therapy ever approved (Casgevy, 2023), and the first new class of non-opioid painkiller in over 20 years (Journavx, 2025). Its next kidney drug, povetacicept, is not first: Otsuka’s Voyxact was approved in 2025, and Vera’s atacicept was filed with the FDA, both working in a similar way. Vertex is betting that povetacicept is better, with a small monthly injection at home.

The competition

In cystic fibrosis, Vertex has no serious rival. In its other markets it is the challenger. Casgevy competes with older stem-cell transplants and with gene therapies from other companies, and it is slow to grow because each patient needs months of hospital care. Journavx has to replace cheap generics and opioids. In IgA nephropathy, the timing of the FDA decision on 30 November 2026 matters, because the drugs approved first set the price.

Money

Vertex is very profitable and has $9.8 billion of cash, even after spending about $9 billion net on Crinetics and on buying back its own shares (paid for in part with a $4.5 billion loan). Costs are rising fast as it runs many late-stage trials at once: the 2026 forecast for research and sales costs went up to $7.15–7.2 billion.

Patents

The cystic fibrosis medicines are protected into the late 2030s, and Alyftrek pushes that further. That gives Vertex many years to make its other medicines grow before its main business faces copies.

Risks

• Concentration. Around 95% of sales still come from cystic fibrosis.
• Slow launches. Casgevy and Journavx have grown more slowly than investors hoped.
• FDA decisions. Povetacicept (November 2026), and later inaxaplin and suzetrigine for nerve pain (2027), can each move the stock sharply.
• Higher spending while the new products are still small.

Our take

Vertex is a high-quality company: a protected cash machine run by people with a record of real scientific firsts. The question for the next two years is whether its new medicines (pain, kidney, hormones, diabetes) can become a second leg as big as cystic fibrosis. The povetacicept decision on 30 November 2026 is the next test.